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Adipose tissue is both an energy storage depot and an endocrine organ. The impaired regulation of the secreted
proteins of adipose tissue, known as adipocytokines, observed during obesity contributes to the onset of whole-body
insulin resistance and the pathobiology of type 2 diabetes mellitus (T2DM). In addition, the global elevation of the
intracellular glycosylation of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) via either genetic or pharmacological
methods is sufficient to induce insulin resistance in both cultured cells and animal models. The elevation of global
O-GlcNAc levels is associated with the altered expression of many adipocytokines. We have previously characterized the
rodent adipocyte secretome during insulin sensitive and insulin resistant conditions. Here, we characterize and quantify
the secretome and glycome of primary human adipocytes during insulin responsive and insulin resistant conditions
generated by the classical method of hyperglycemia and hyperinsulinemia or by the pharmacological manipulation of
O-GlcNAc levels. Using a proteomic approach, we identify 190 secreted proteins and report a total of 20 up-regulated and
6 down-regulated proteins that are detected in both insulin resistant conditions. Moreover, we apply glycomic techniques
to examine (1) the sites of N-glycosylation on secreted proteins, (2) the structures of complex N- and O-glycans, and (3)
the relative abundance of complex N- and O-glycans structures in insulin responsive and insulin resistant conditions. We
identify 91 N-glycosylation sites derived from 51 secreted proteins, as well as 155 and 29 released N- and O-glycans
respectively. We go on to quantify many of the N- and O-glycan structures between insulin responsive and insulin
resistance conditions demonstrating no significant changes in complex glycosylation in the time frame for the induction
of insulin resistance. Thus, our data support that the O-GlcNAc modification is involved in the regulation of adipocytokine
secretion upon the induction of insulin resistance in human adipocytes.
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Type 2 diabetes mellitus (T2DM) is a rapidly growing
problem in the industrialized world. In the United States,
it is estimated that 8.3% of the population has diabetes [1].
T2DM results from a combination of insulin resistance
and pancreatic beta-cell dysfunction [2]. The development
of T2DM depends on both genetic and environmental risk
factors [3]. The major environmental risk factor for the
development of insulin resistance and T2DM is obesity.
Increased white adipose tissue (WAT) mass during obesity
causes a variety of problems related to the development* Correspondence: lwells@ccrc.uga.edu
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unless otherwise stated.of insulin resistance. It is now established that WAT acts
as a lipid metabolism modulator as well as an endocrine
organ [4].
The secreted proteins of adipose tissue, known as adi-
pocytokines, can act in a paracrine or endocrine manner
to modulate a variety of processes such as inflammation
and whole-body energy homeostasis. During obesity, adi-
pocytokine secretion is altered, which can lead to the de-
velopment of whole-body insulin resistance and T2DM
[5,6]. Although many adipocytokines have been identified
using methods such as mass spectrometry-based proteo-
mics, the alteration in the adipose tissue secretome for
normal vs. insulin resistant human adipose tissue has not
been well-defined [7]. Several adipocytokines identified
in rodents have different expression patterns in humans
highlighting the need for quantitative proteomic studies. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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logical representation of the adipose tissue secretome, we
use primary human pre-adipocytes derived from human
adipose tissue rather than an adipocyte cell line [10].
The regulation of adipocytokine expression during insu-
lin resistance is still unclear in many cases. One possible
way for cells to sense nutrient abundance and modulate in-
sulin sensitivity and adipocytokine expression is through
the hexosamine biosynthetic pathway (HBP). Excessive flux
through the HBP results in insulin resistance, thereby lim-
iting the amount of glucose that enters the cell and the
resulting toxicity [11,12]. Flux through the HBP also mod-
ulates the expression of several adipocytokines [13-16].
The final product of the HBP is UDP-GlcNAc, which is
the sugar donor for the enzyme O-GlcNAc transferase
(OGT) that adds the O-linked β-N-acetylglucosamine
(O-GlcNAc) modification onto the serine and threonine
residues of nucleocytosolic proteins [17,18]. It has been
shown in multiple systems that the elevation of O-GlcNAc
levels is sufficient to cause insulin resistance [19-24]. Fur-
thermore, the overexpression of OGT in the peripheral
tissues of mice results in both glucose disposal defects
and hyperleptinemia providing further evidence that the
O-GlcNAc modification causes insulin resistance and
the dysregulation of adipocytokine expression [21]. We
have previously characterized and quantified the secre-
tome of rodent adipocytes during insulin resistance gener-
ated by either directly or indirectly modulating O-GlcNAc
levels [25]. We use a similar approach in this study.
Insulin resistance is induced in primary human adipo-
cytes by either the classical method of chronic hyper-
insulinemia and hyperglycemia or by directly elevating
O-GlcNAc levels using O-GlcNAcase (OGA) pharmaco-
logical inhibitors. To identify and quantify the secretome
we use a proteomic approach with reverse phase (RP) li-
quid chromatography-nanospray-tandem mass spectrom-
etry (LC-NS-MS/MS). We identify a total of 190 secreted
proteins from primary human adipocytes. We compare the
relative abundance of the adipocytokines during insulin re-
sponsive versus insulin resistant conditions using spectral
counts. We report that 20 proteins are upregulated and 4
are downregulated when primary human adipocytes are
shifted from insulin sensitive to insulin resistant conditions.
Glycosylation is one of the most common post-trans
lational modifications (PTMs) of proteins, especially of
secreted proteins [26-34]. In certain disease states, the gly-
come and the enzymes responsible for the glycan complex-
ity can be altered [35,36]. It has been suggested that the
increased pool of UDP-GlcNAc during excessive nutrient
flux alters glycosyltransferase activity and the degree
of N-glycan branching [37]; however, another study re-
ported no change in complex glycosylation during ele-
vated HBP flux [38]. Determining the glycome in different
disease states is important for the future identification ofstructure-function relationships and to discover targets
for diagnostic biomarkers [25,39,40]. The glycome of hu-
man adipose tissue has not been previously described.
Glycan analysis is challenging due to the diversity of pos-
sible structures and their low abundance [35,41-49]. We
use several strategies to identify, site-map, and quantify
glycans from adipose tissue using mass spectrometry
(MS). We characterize a total of 155 N-linked glycans and
29 O-linked glycans using MS/MS spectra by total ion
mapping (TIM) scan. Predominant N-linked and O-linked
glycans can be quantified by 13C isotopic labeling by per-
methylation using heavy or light iodomethane (13CH3I
and 12CH3I) and isobaric pairs of iodomethane (
13CH3I
or 12CH2DI) (48, 49). A total of 48 N-linked glycans and
12 O-linked glycans are compared between the insulin
responsive condition and both insulin resistance condi-
tions by calculating the 13C/12C ratios from the sum of
peak areas and from non-labeled prevalence rates. We also
identify 91 N-glycosylation sites derived from 51 secreted
proteins using the PNGase F digestion in 18O water using
a parent mass list method.
Herein, we describe the secretome and glycome of pri-
mary human adipocytes during insulin sensitive and insu-
lin resistant condition. Given the important physiological
roles of adipocytokines in maintaining whole-body energy
homeostasis, the characterization of the primary human
adipocyte secretome during insulin resistance could pro-
vide novel markers and/or therapeutic targets for the on-
set of insulin resistance.
Experimental procedures
Tissue culture and conditioned cell treatments
Cryopreserved human subcutaneous preadipocytes (num-
ber of donors: 6–7, gender of donors: female, average age:
39, and average BMI: 27.32) were purchased from Zen-Bio,
Inc. (Research Triangle Park, NC). The adipose tissue cul-
ture protocols of the maintenance and differentiation from
preadipocytes to adipocytes were based on Zen-Bio instruc-
tion manual (ZBM0001.01). Briefly approximately 6.7 × 105
cells were cultured in a T-75 cm2 culture flask using preadi-
pocyte medium (PM-1, Zen-Bio, Inc.), under a humidified
atmosphere containing 5% CO2 in air at 37°C until they
were 85-90% confluent, and then were trypsinized for
5 minutes at 37°C. After neutralization and centrifuga-
tion steps, the cell pellet was resuspended in PM-1 and
seeded at an average density of 2.67 × 104 cells/cm2 in
10-cm cell culture dishes for differentiation. 2 days
after the cells reached confluence (referred to as day 0),
the medium was replaced with adipocyte differentiation
medium (DM-2, Zen-Bio, Inc.). On day 7, the DM-2 was
removed and the cells were maintained in adipocyte main-
tenance medium (AM-1, Zen-Bio, Inc.). The medium was
changed every 3 days. On day 15, at which the majority of
the cells contained large lipid droplets, the AM-1 medium
Lim et al. Clinical Proteomics 2014, 11:20 Page 3 of 23
http://www.clinicalproteomicsjournal.com/content/11/1/20was replaced with low glucose DMEM (Cellgro, Mediatech,
Inc.) containing 10% FBS (GIBCO, Invitrogen) and antibi-
otics (100 units/mL penicillin and 100 μg/mL streptomycin
(P/S), Cellgro, Mediatech, Inc.). The medium was changed
every 2 days until treatments were applied. On day 20,
adipocytes were treated with different conditions, either
(1) low glucose (LG) (LG, DMEM containing 10% FBS
and P/S), (2) insulin (100 nM, human, Roche) in high
glucose (HG + INS) (HG, DMEM containing 10% FBS
and P/S), (3) PUGNAc (100 μM, TRC, Inc.) in low glu-
cose (LG + PUGNAc) (LG, DMEM containing 10% FBS
and P/S), or (4) GlcNAcstatin (20 nM, kind gift from Dr.
Daan van Aalten) in low glucose (LG + PUGNAc) (LG,
DMEM containing 10% FBS and P/S). After the first 24 h
of incubation, the cells were washed five times (for mass
spectrometry analysis) or 3 times (for immunoblotting)
with low or high glucose serum-free DMEM without anti-
biotics and incubated for 15 min during the last rinse. After
the final wash, the treatment conditions were added as
above except no serum was added and the HG+ INS treat-
ment was changed to 1nM Insulin. The cells and media
were harvested after 16 h of incubation.
Secreted protein sample preparation
The conditioned media was harvested with extreme care
not to disrupt underlying cells and then centrifuged once
at 1800 rpm, at 4°C for 7 min. The supernatant was fil-
tered using 1 μm syringe filters (PALL). The samples were
then centrifuged again at 30000 × g, at 4°C for 30 min. The
samples were then transferred to equilibrated spin col-
umns (Centriprep YM-3, Amicon, Millipore) and buffer-
exchanged at 2800 × g, at 4°C into 40 mM ammonium
bicarbonate (NH4HCO3) in the presence of 1 mM di-
thiothreitol (DTT, Fisher Scientific) and concentrated. The
samples were either quantified and prepared for immuno-
blotting or were denatured with 1 M urea (Sigma), reduced
with 10 mM DTT for 1 h at 56°C, carboxyamidomethylated
with 55 mM iodoacetamide (ICH2CONH2, Sigma) in the
dark for 45 min, and then digested with 4 μg of trypsin
(Promega) in 40 mM NH4HCO3 overnight at 37°C. After
digestion, the peptides were acidified with 200 μL of 1% tri-
fluoroacetic acid (TFA). Desalting was subsequently per-
formed with C18 spin columns (Vydac Silica C18, The Nest
Group, Inc.) and the resulting peptides were dried down in
a Speed Vac and stored at −20°C until analysis. For the sub-
set of samples to be analyzed for N-linked glycosylation,
peptides were resuspended in 19 μL of 18O water (H2
18O,
95%, Cambridge Isotope Laboratories, Inc.) and 1 μL of
N-Glycosidase F (PNGase F, Prozyme) and allowed to in-
cubate for 18 h at 37°C. Peptides were dried back down
and resuspended in 50 μL of 40 mM NH4HCO3, with
1 μg of trypsin for 4 hr, to remove any possible C-terminal
incorporation of 18O from residual trypsin activity, and
then dried down and stored at −20°C until analysis.Whole cell extracts and western blots
After culture medium was removed for secreted proteins
analysis, the cell monolayer was washed twice with 10 ml
of ice-cold PBS and scraped in the presence of 1 ml PBS
plus protease inhibitors. After removing PBS by centrifuga-
tion at 6,000 × g for 5 min at 4°C, the pellet was snap frozen
and stored at −80°C. To prepare lysate for immunoblotting,
the pellets were lysed in 20 mM Tris pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 1:100 protease inhibitor
cocktail set V, EDTA-free (Calbiochem), and 1 uM PUG-
NAc. Protein concentration was determined using the
Pierce BCA Protein Assay Kit (Thermo Scientific) and
samples were boiled in Laemli sample buffer. The im-
munoblots were performed essentially as described [50]
using CTD 110.6 (for O-GlcNAc modified proteins) and
ERK-2 (as a positive control for loading) antibodies. For
secreted protein immunoblotting, the media concentra-
tion was quantified using the Bradford method and veri-
fied by Coomassie staining. Equal amounts of protein
were separated by SDS-PAGE with Tris–HCl precast
minigels (Bio-Rad) and transferred to nitrocellulose mem-
branes for Western blot analysis. After blocking for at
least 1 hour, membranes were incubated with the appro-
priate primary antibody, anti-SPARC (Abcam) or anti-
Chitinase-3-like protein 1 (R&D Systems) overnight at
4°C. Membranes were incubated with the appropriate
horseradish peroxidase-coupled secondary antibodies for
1 hour, followed by extensive washing and Pierce ECL
detection.
Protein extracts for glycan analysis
After the conditioned media was collected, the adipo-
cytes were immediately washed twice with ice-cold PBS
and harvested by scraping for glycan analysis. The cells
were centrifuged at 12,000 × g, at 4°C for 15 min to re-
move the supernatant and debris, then snap frozen and
stored at −80°C until analysis. After the cell pellets thawed
on ice, the samples were subjected to Dounce homoge-
nization in ice-cold 100% methanol. The homogenized
samples were delipidated by two solvent extractions using
a mixture of chloroform/methanol/water (4:8:3, v/v/v) and
rocking for 3 h at room temperature as described previ-
ously [35,40]. The emulsion was centrifuged at 2800 × g for
15 min at 4°C to remove the supernatant. The pellets were
resuspended in an acetone/water (10:1, v/v) mixture and
incubated on ice for 15 min for washing. The protein pel-
lets were collected by centrifugation and dried on a heating
module at 45°C under a mild nitrogen stream (Reacti-
Therm™ and Reacti-Vap™, Pierce). The dried protein pow-
der was weighed and stored at −20°C until analysis.
Preparation of N-linked glycans
Three mg of the protein powder was resuspended in
200 μL of 40 mM NH4HCO3 by sonication followed by
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perature, 25 μL of trypsin (2 mg/mL in 40 mM NH4HCO3,
Sigma) and chymotrypsin (2 mg/mL in 40 mM NH4HCO3,
Sigma) were added. The samples were denatured with
250 μL of 2 M urea in 40 mM NH4HCO3, leading to a final
concentration of 1 M urea, and incubated overnight (18 h)
at 37°C. After digestion, the peptide samples were cen-
trifuged and 10 μL of the supernatant was collected for
protein quantification. The peptide concentrations were
measured using a Pierce BCA Protein Assay Kit (Thermo
Scientific). The samples were boiled at 100°C for 5 min
and then acidified by adding 500 μL of 10% acetic acid
(AcOH) to deactivate proteases. The samples were loaded
onto an equilibrated C18 extraction column (BakerBond™,
J.T.Baker), washed with 1 mL of 5% AcOH three times,
and then eluted stepwise using 1 mL of 20% isopropanol
in 5% AcOH, 40% isopropanol in 5% AcOH, and 100%
isopropanol. The resulting glycopeptides were dried in a
Speed Vac, resuspended in 48 μL 1× PNGase F reaction
buffer and 2 μL PNGase F and incubated for 18 h at 37°C.
Following PNGase F digestion, released oligosaccharides
were separated by the C18 extraction column. The mix-
ture was reconstituted in 5% AcOH and loaded onto an
equilibrated C18 extraction column. The N-linked oligo-
saccharides were eluted using 1 mL of 5% AcOH three
times and then collected and dried using a Speed Vac for
subsequent permethylation.
Preparation of O-linked glycans
O-linked oligosaccharides were released by reductive β-
elimination then purified by a cation exchange resin. Three
mg of delipidated protein powder was weighed and trans-
ferred into a clean glass tube. 500 μL of 50 mM sodium
hydroxide (NaOH) and 500 μL of alkaline borohydride so-
lution (a mixture of 2 M sodium borohydride (NaBH4,
Sigma-Aldrich) in 50 mM NaOH leading to a final con-
centration of 1 M NaBH4) were added to the tube. The
mixture was incubated for 16 h at 45°C on the heating
block and the reaction was stopped by the addition of 10%
AcOH with vortexing. The acidified mixture was loaded
onto an equilibrated cation exchange resin cartridge (AG
50 W-X8, Bio-Rad) with 5% AcOH. O-linked glycans were
eluted with 6 mL of 5% AcOH and then dried in a Speed
Vac. The sample was resuspended in 1 mL methanol/
glacial acetic acid (9:1, v/v) solution and dried on the
heating module at 45°C under a mild nitrogen stream to
remove borates for subsequent permethylation.
Permethylation of glycans
To facilitate analysis of oligosaccharides by mass spectrom-
etry, the released oligosaccharide mixtures were permethy-
lated as described previously [35,39,51]. Briefly, glycans
were resuspended in 200 μL of anhydrous dimethyl sulfox-
ide (DMSO, Sigma-Aldrich) and 250 μL of fresh dehydratedNaOH/DMSO reagent (mixture of 50 mg NaOH in 2 mL
of anhydrous DMSO). After sonication and vortexing under
nitrogen gas, 100 μL of 12C or 13C-iodomethane (12CH3I
and 13CH3I, 99% of
13C, Sigma-Aldrich) was added and the
mixtures were vortexed vigorously for 5 min. 2 mL of dis-
tilled water was added to the samples and the excess iodo-
methane was removed by bubbling with a nitrogen stream.
Two mL of dichloromethane (CH2Cl2, Sigma-Aldrich) was
added. After vigorous mixing and phase separation by cen-
trifugation, the upper aqueous layer was removed and dis-
carded. The nonpolar organic phase was then extracted 4
times with distilled water. Dichloromethane was evaporated
on the heating module at 45°C with a mild nitrogen stream.
The permethylated glycans were dissolved in adjusted vol-
umes (15–30 μL) of 100% methanol according to the results
of the protein assay. The 12C and 13C-labeled permethylated
glycans were mixed in the same proportion for each experi-
mental condition before analysis.
Analysis using mass spectrometry
For proteome analysis of secreted proteins by liquid chro-
matography tandem mass spectrometry (LC-MS/MS), the
peptides were resuspended with 19.5 μL of mobile phase A
(0.1% formic acid, FA, in water) and 0.5 μL of mobile phase
B (80% acetonitrile, ACN, and 0.1% formic acid in water)
and filtered with 0.2 μm filters (Nanosep, PALL). The sam-
ples were loaded off-line onto a nanospray tapered capillary
column/emitter (360 × 75 × 15 μm, PicoFrit®, New Object-
ive) that was self-packed with C18 reverse phase (RP) resin
(8.5 cm, Waters) in a nitrogen pressure bomb for 10 min
at 1000 psi (~5 μL load). The samples were then separated
via a 160 min linear gradient of increasing mobile phase
B at a flow rate of ~200 nL/min directly into the mass
spectrometer. One-dimensional LC-MS/MS analysis was
performed using a linear ion trap and an Orbitrap mass
spectrometer (LTQ and LTQ Orbitrap XL, Thermo Fisher
Scientific Inc., San Jose, CA) equipped with a nanoelec-
trospray ion source at 2.0 kV capillary voltage and 200°C
capillary temperature. For secretome analysis, a full ITMS
(Ion trap mass spectrometry) spectrum in positive ion and
profile mode was collected at 300–2000 m/z followed
by 8 MS/MS events on the 8 most intense peaks with
enabled dynamic exclusion using a repeat count of 2, a
maximum exclusion list size of 100, and an exclusion
duration of 30 s. Each MS/MS scan event was followed
by CID (34% normalized collision energy), 0.25 activa-
tion Q, and 30.0 ms activation time. For N-liked glyco-
sylation site mapping, a full FTMS (Fourier transform
mass spectrometry) spectrum, typically recorded at 60000
resolution in positive ion and profile mode, was acquired
at 300–2000 m/z followed by 5 data dependent MS/MS
spectra of ITMS on the most intense ion peaks from parent
mass list following CID (36% normalized collision energy),
0.25 activation Q, and 30.0 ms activation time. Dynamic
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sion list of 100, and an exclusion duration of 60 s.
For glycome analysis by direct infusion nanospray MS,
permethylated glycans were dissolved by combining 15 μL
of the isotopically mixed sample in 100% methanol plus
35 μL 1 mM NaOH in 50% methanol. They were infused
directly into a linear ion trap and an Orbitrap mass spec-
trometer using a nanospray ion source with a fused-silica
emitter (360 × 75 × 30 μm, SilicaTip™, New Objective) at
2.0 kV capillary voltage, 200°C capillary temperature, and
a syringe flow rate of 0.4 μL/min. The full ITMS spectra
and FTMS spectra, typically recorded at 60000 resolution
in positive ion and profile mode, were collected at 400–
2000 m/z for 30 s with 5 microscans and 150 maximum
injection times (ms). The centroid MS/MS spectra follow-
ing collision-induced dissociation (CID) were obtained
from 400 to 2000 m/z at 34% and 28% normalized colli-
sion energy for N- and O-linked glycans, respectively, 0.25
activation Q, and 30.0 ms activation time by total ion
mapping (TIM). Parent mass step size and isolation width
were set at 2.0 m/z and 2.8 m/z, respectively, for auto-
mated MS/MS spectra with TIM scans.
Data analysis
The resulting proteomic data was searched against a target
nonredundant human (Homo sapiens, 5-2-07) database
including the common contaminants database obtained
from the human International Protein Index (IPI) protein
sequence database (European Bioinformatics Institute, ftp://
ftp.ebi.ac.uk/pub/databases/IPI) using the TurboSequest
algorithm (BioWorks 3.3.1 SP1, Thermo Fisher Scientific
Inc.) [52,53]. It was also searched against a decoy human
database to determine statistically relevant peptide
identification. DTA files were generated for spectra
with a threshold of 15 ions and a TIC of 2e3 over a range of
[MH]+ = 600–4000 for only IT data. The SEQUEST param-
eters were set to allow 2.0 Da (20 ppm for FT) of precursor
ion mass tolerance and 0.5 Da of fragment ion tolerance
with monoisotopic mass. Only strict tryptic peptides were
allowed with up to two missed internal cleavage sites.
Dynamic mass increases of 15.99 and 57.02 Da (15.9949
and 57.0215 Da for FT) were allowed for oxidized methio-
nine and alkylated cysteine, respectively. In the cases where
sites of N-linked glycosylation were investigated with
PNGase F and 18O water, a dynamic mass increase of
3.0 Da (2.9883 Da for FT) was allowed for Asn residues
[54]. The masses were selected between 300–2000 m/z at
each charge state and 7352 total masses were obtained for
parent mass list. Each sample was analyzed by four LC-MS/
MS runs with different parent mass list up to 2000 because
of maximum number of parent masses for FTMS and mass
complexity. The results from shotgun method and parent
mass list method were combined and filtered at ≥ 0.60 Final
Score (Sf). For relative protein quantification, the identifiedpeptides and proteins were statistically validated between
the target and decoy database search results, and protein
ratios were determined by normalized spectral counts using
ProteoIQ 1.1 (Premiere BioSoft). Proteins identified by two
peptides were only considered to be statistically significant
at less than 1% protein false discovery rate (FDR) using the
ProValT algorithm as implemented in ProteoIQ [55,56].
From the results, the subcellular location of secreted pro-
teins was manually determined for each protein from the
Human Protein Reference Database (http://www.hprd.org/),
Information Hyperlinked Over Proteins (iHOP, http://
www.ihop-net.org/UniPub/iHOP/) and the UniProtKB/
Swiss-Prot (http://www.ebi.ac.uk/uniprot) databases. The
functional categories of secretome were annotated by the
Ingenuity Pathways Analysis program (IPA, Ingenuity
Systems, Inc.).
The N- and O-linked glycans released from the protein
power of adipocytes were analyzed by full MS following
permethylation and subsequent MS/MS fragmentations
for specific glycan structures. We used GlycoWorkbench
(http://glycomics.ccrc.uga.edu/eurocarb/gwb/home.action)
to facilitate manually interpretation of the glycan struc-
tures from the MS/MS spectra by TIM scan. The areas of
each isotopic peak were calculated by their Gaussian distri-
bution and then averaged to compare the relative abun-
dance of each glycan between different samples. The ratio
of peak areas from isotopic permethylation defined the
relative abundance of each glycan.
Results
Insulin resistance and global O-GlcNAc levels in primary
human adipocytes
Treatment with hyperglycemia and chronic insulin or
normoglycemia and the pharmacological OGA inhibitor,
PUGNAc, result in the global elevation of O-GlcNAc
modified nucleocytosolic proteins and insulin resistance
in rodent adipocytes [19,57]. We tested these conditions
as well as treatment with a more specific OGA inhibitor,
GlcNAcstatin, in primary human adipocytes [58]. Cryo-
preserved human preadipocytes were expanded and dif-
ferentiated into mature adipocytes before treatment as
described in Materials and Methods. Figure 1 shows that
when compared to normoglycemia (LG), treatment with
OGA inhibitors (LG + PUGNAc or LG +GlcNAcstatin)
or treatment with hyperglycemia and hyperinsulinemia
(HG + INS) raises global O-GlcNAc levels as measure by
immunoblotting with an O-GlcNAc specific antibody. In a
previous study using rodent adipocytes, we characterized
and quantified the secretome and glycome during insulin
sensitive and insulin resistant conditions induced by indir-
ectly (HG + INS) or directly (LG + PUGNAc) modulating
O-GlcNAc levels. We found that many secreted proteins
were up or down-regulated upon the induction of insulin
resistance. Here we took a parallel approach to ask the
Figure 1 Detection of O-GlcNAc levels in primary human adipocytes. Global O-GlcNAc levels are elevated in three insulin resistant conditions
generated by low glucose plus PUGNAc (LG + PUGNAc), low glucose plus GlcNAcstatin (LG + GlcNAcstatin), or high glucose plus chronic insulin
exposure (HG + INS).
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in Figure 2, after treatment both the cells and conditioned
media were harvested. Before the final 16 hour serum-free
treatment incubation, the cells were washed five times with
serum-free media to remove any traces of serum. This
greatly reduced the complexity of the conditioned media.
The conditioned media was buffer exchanged and concen-
trated before being processed for analysis by LC-MS/MS.
Cells were collected and delipidated as in Materials and
Methods. Protein was digested and prepared for either N-
glycan or O-glycan analysis (Figure 2).
Characterization of the primary human adipose tissue
secretome by LC-MS/MS
The mass spectra from 24 mass spectrometric analyses
were searched against a target nonredundant human data-
base as well as a decoy human database using SEQUEST.Proteins identified by at least two non-redundant peptides
with less than a 1% FDR were identified using ProteoIQ.
Secreted proteins were manually determined by a refer-
ence search as described in Materials and Methods. Using
these criteria, a total of 190 secreted proteins were identi-
fied. Table 1 shows the complete list of the 173 secreted
proteins identified by at least 2 unique peptides. 17 of
the secreted proteins identified based on a single pep-
tide are presented in Supplemental Table 1 (Additional
file 1: Table S1). Figure 3 shows the proportion of the secre-
tome in each of the 9 main functional categories assigned
by Ingenuity Pathways Analysis. The most highly repre-
sented categories are enzyme, peptidase, and other protein.
Quantification of the primary human adipocyte secretome
Several mass spectrometry techniques can be used for
quantitative analysis. Both isotopic and non-isotopic
Figure 2 Schematic flow diagram of the experimental procedure. (A) Primary human adipocytes are treated with insulin responsive (LG,
normoglycemic) or two insulin resistance generating conditions (HG + INS and LG + PUGNAc). (B) Identification and quantification of the secretory
proteome and N-linked glycosylation site-mapping from the conditioned media of treated primary human adipocytes (C) Characterization and
quantification of N- and O-linked glycans from a whole protein extract of treated primary human adipocytes.
Lim et al. Clinical Proteomics 2014, 11:20 Page 7 of 23
http://www.clinicalproteomicsjournal.com/content/11/1/20labeling are commonly used to provide quantitative ana-
lysis of proteins in complex protein samples [59-67]. For
non-isotopic or label-free MS-based quantitative analysis,
ion chromatogram intensity or observed peptide spectral
counts are compared using quantitative software tools
[68-76]. Peptide spectral counts quantification relies on the
association between protein abundance and the number of
MS/MS spectra identifying each protein. For this study, we
used three biological replicates of conditioned media sam-
ples, which differed in complex proteome profiles and
relative number of normalized spectral counts. For each
of the biological replicates, prepared conditioned media
from three treatment groups (LG, LG + PUG, HG+ INS)
was subjected to two technical replicates of reverse phase
LC-MS/MS. All together, a total of 18 LC-MS/MS experi-
ments were performed. SEQUEST was used to search MS
data files from each LC-MS/MS run against a forward and
reversed human database to calculate a FDR. ProteoIQ
was used to cluster the peptides to their assigned proteins
and to gather normalized spectral counts for proteins
identified at less than a 1% FDR and assigned by at least
two non-redundant peptides. Spectral counts were nor-
malized for each technical replicate. For each biological
replicate the normalized spectral counts were averaged
followed and then the comparative ratios between the two
insulin resistant conditions and the insulin responsive
condition were calculated. Finally, the comparative ratios
were averaged between all of the biological replicates. We
set the threshold for reporting statistically significant differ-
ences at ≥150% (1.5-fold), an average of ≥5 total spectral
counts, and an average of ≥3 normalized spectral countsfor each treatment group. We identified 20 human adipo-
cytokines whose secretion levels were upregulated and 4
proteins that were downregulated by at least 1.5-fold by
the transition from the insulin sensitive condition to both
insulin resistant conditions (Table 2). We also identified 28
and 8 proteins that were upregulated or downregulated, re-
spectively, in the transition from insulin sensitive to one of
the insulin resistant conditions (Additional file 1: Table S2).
To confirm the validity of the ratio that we used for
statistical significance, we used the orthogonal method
of immunoblotting. We confirmed that the regulation
we observed in the proteomic experiment with immuno-
blotting for two proteins whose levels changed by only
1.5-fold in at least one of the insulin resistant conditions
as determined by proteomics. In addition, we used cells
where insulin resistance was induced using a more spe-
cific OGA inhibitor, GlcNAcstatin, to confirm the regula-
tion we observed by using the less specific OGA inhibitor,
PUGNAc [58,77]. Figure 4 shows that both SPARC and
Chitinase-3-like protein 1 are upregulated in both insulin
resistant conditions as determined by immunoblotting,
which confirms our proteomic experiment.
N-glycan site-mapping of the human adipocyte secretome
Many secreted proteins are modified by N-glycans. During
disease states, the glycoforms of these proteins may change
and have the potential to be used as disease biomarkers.
Since the glycome of adipocytes is not well-defined, we de-
termine sites of N-linked glycosylation on secreted adipo-
cytokines as an initial step in biomarker discovery. The
tryptic peptides generated from conditioned media were
Table 1 Total secreted proteins from human dispose tissue by LC-MS/MS
No. Protein ID Identifed proteins Subcellular locationa
1 Q92484 Acid sphingomyelinase-like phosphodiesterase 3a Extracellular
2 P07108 Acyl-CoA-binding protein Cytoplasm
3 Q8IUX7 Adipocyte enhancer-binding protein 1 Membrane
4 P01023 Alpha-2-macroglobulin Nucleus
5 P06733 Alpha-enolase Extracellular
6 P15144 Aminopeptidase N Cytoplasm
7 P01019 Angiotensinogen Membrane
8 P07355 Annexin A2 Extracellular
9 P08758 Annexin A5 Membrane
10 Q8NCW5 Apolipoprotein A-I binding protein Extracellular
11 P05090 Apolipoprotein D Extracellular
12 P02649 Apolipoprotein E Extracellular
13 P15289 Arylsulfatase A Cytoplasm
14 P61769 Beta-2-microglobulin Membrane
15 P21810 Biglycan Extracellular
16 P43251 Biotinidase Extracellular
17 P55290 Cadherin-13 Membrane
18 P27797 Calreticulin Cytoplasm
19 O43852 Calumenin Cytoplasm
20 P16870 Carboxypeptidase E Membrane
21 P49747 Cartilage oligomeric matrix protein Extracellular
22 P07858 Cathepsin B Cytoplasm
23 P07339 Cathepsin D Cytoplasm
24 P43235 Cathepsin K Cytoplasm
25 P07711 Cathepsin L Cytoplasm
26 Q9UBR2 Cathepsin Z Cytoplasm
27 P36222 Chitinase-3-like protein 1 Extracellular
28 Q15782 Chitinase-3-like protein 2 Extracellular
29 Q59FG9 Chondroitin sulfate proteoglycan 2 (versican) variant Extracellular
30 P10909 Clusterin Extracellular
31 P02452 Collagen alpha-1(I) chain Extracellular
32 P02458 Collagen alpha-1(II) chain Extracellular
33 P02461 Collagen alpha-1(III) chain Extracellular
34 P02462 Collagen alpha-1(IV) chain Extracellular
35 P20908 Collagen alpha-1(V) chain Extracellular
36 P12109 Collagen alpha-1(VI) chain Extracellular
37 Q02388 Collagen alpha-1(VII) chain Extracellular
38 P12107 Collagen alpha-1(XI) chain Extracellular
39 Q99715 Collagen alpha-1(XII) chain Extracellular
40 P39059 Collagen alpha-1(XV) chain [Contains: Endostatin] Extracellular
41 P39060 Collagen alpha-1(XVIII) chain [Contains: Endostatin] Extracellular
42 P08123 Collagen alpha-2(I) chain Extracellular
43 P08572 Collagen alpha-2(IV) chain [Contains: Canstatin] Extracellular
44 P05997 Collagen alpha-2(V) chain Extracellular
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Table 1 Total secreted proteins from human dispose tissue by LC-MS/MS (Continued)
45 P12110 Collagen alpha-2(VI) chain Extracellular
46 P25940 Collagen alpha-3(V) chain Extracellular
47 P12111 Collagen alpha-3(VI) chain Extracellular
48 P08253 Collagenase (72 kDa type IV) Extracellular
49 P00736 Complement C1r subcomponent Extracellular
50 P09871 Complement C1s subcomponent Extracellular
51 P01024 Complement C3 Extracellular
52 P29279 Connective tissue growth factor Extracellular
53 Q9Y240 C-type lectin domain family 11 member A Extracellular
54 O75462 Cytokine receptor-like factor 1 Extracellular
55 P07585 Decorin Extracellular
56 Q07507 Dermatopontin Extracellular
57 Q4VWZ6 Diazepam binding inhibitor, splice form 1c Cytoplasm
58 Q9UBP4 Dickkopf-related protein 3 Extracellular
59 Q14118 Dystroglycan Membrane
60 Q13822 Ectonucleotide pyrophosphatase/phosphodiesterase 2 Membrane
61 Q12805 EGF-containing fibulin-like extracellular matrix protein 1 Extracellular
62 O95967 EGF-containing fibulin-like extracellular matrix protein 2 Extracellular
63 Q9Y6C2 EMILIN-1 Extracellular
64 Q9BXX0 EMILIN-2 Extracellular
65 P61916 Epididymal secretory protein E1 Extracellular
66 Q9Y2E5 Epididymis-specific alpha-mannosidase Cytoplasm
67 Q16610 Extracellular matrix protein 1 Extracellular
68 P08294 Extracellular superoxide dismutase [Cu-Zn] Extracellular
69 P35555 Fibrillin-1 Extracellular
70 Q53TP5 Fibroblast activation protein, alpha subunit Cytoplasm
71 Q06828 Fibromodulin Extracellular
72 P02751 Fibronectin Membrane
73 P23142 Fibulin-1 Extracellular
74 P98095 Fibulin-2 Extracellular
75 Q9UBX5 Fibulin-5 Extracellular
76 Q12841 Follistatin-related protein 1 Extracellular
77 P16930 Fumarylacetoacetase Cytoplasm
78 P09382 Galectin-1 Extracellular
79 Q08380 Galectin-3-binding protein Membrane
80 Q92820 Gamma-glutamyl hydrolase Cytoplasm
81 P06396 Gelsolin Extracellular
82 Q9UJJ9 GlcNAc-1-phosphotransferase subunit gamma Cytoplasm
83 P07093 Glia-derived nexin Extracellular
84 P04406 Glyceraldehyde-3-phosphate dehydrogenase Cytoplasm
85 P35052 Glypican-1 Membrane
86 P28799 Granulins Extracellular
87 Q14393 Growth-arrest-specific protein 6 Extracellular
88 P00738 Haptoglobin Extracellular
89 P00739 Haptoglobin-related protein Extracellular
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Table 1 Total secreted proteins from human dispose tissue by LC-MS/MS (Continued)
90 O75629 Human Protein CREG1 Nucleus
91 P17936 Insulin-like growth factor-binding protein 3 Extracellular
92 P22692 Insulin-like growth factor-binding protein 4 Extracellular
93 P24592 Insulin-like growth factor-binding protein 6 Extracellular
94 Q16270 Insulin-like growth factor-binding protein 7 Extracellular
95 O95965 Integrin beta-like protein 1 Unknown
96 P19823 Inter-alpha-trypsin inhibitor heavy chain H2 Extracellular
97 O14498 ISLR Extracellular
98 Q08431 Lactadherin Extracellular
99 Q8NHP8 LAMA-like protein 2 Extracellular
100 Q59H37 Laminin alpha 2 subunit isoform b Extracellular
101 Q16363 Laminin subunit alpha-4 Extracellular
102 P07942 Laminin subunit beta-1 Extracellular
103 P55268 Laminin subunit beta-2 Extracellular
104 P11047 Laminin subunit gamma-1 Extracellular
105 Q14767 Latent-transforming growth factor beta-binding protein 2 Extracellular
106 Q99538 Legumain Cytoplasm
107 Q07954 Low-density lipoprotein receptor-related protein 1 Membrane
108 P51884 Lumican Extracellular
109 P10619 Lysosomal protective protein Cytoplasm
110 P13473 Lysosome-associated membrane glycoprotein 2 Membrane
111 Q9Y4K0 Lysyl oxidase homolog 2 Extracellular
112 P09603 Macrophage colony-stimulating factor 1 Extracellular
113 Q9UM22 Mammalian ependymin-related protein 1 Nucleus
114 P48740 Mannan-binding lectin serine protease 1 Extracellular
115 P50281 Matrix metalloproteinase-14 Extracellular
116 P01033 Metalloproteinase inhibitor 1 Extracellular
117 P16035 Metalloproteinase inhibitor 2 Extracellular
118 Q71SW6 Muscle type neuropilin 1 Membrane
119 P14543 Nidogen-1 Extracellular
120 Q14112 Nidogen-2 Extracellular
121 Q02818 Nucleobindin-1 Cytoplasm
122 Q9NRN5 Olfactomedin-like protein 3 Extracellular
123 Q86UD1 Out at first protein homolog Unknown
124 P26022 Pentraxin-related protein PTX3 Extracellular
125 P62937 Peptidyl-prolyl cis-trans isomerase A Cytoplasm
126 P23284 Peptidylprolyl isomerase B Cytoplasm
127 Q15063 Periostin Extracellular
128 P98160 Perlecan Membrane
129 Q92626 Peroxidasin homolog Unknown
130 P30086 Phosphatidylethanolamine-binding protein 1 Cytoplasm
131 P55058 Phospholipid transfer protein Extracellular
132 P36955 Pigment epithelium-derived factor Extracellular
133 Q9BTY2 Plasma alpha-L-fucosidase Extracellular
134 Q9Y646 Plasma glutamate carboxypeptidase Extracellular
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Table 1 Total secreted proteins from human dispose tissue by LC-MS/MS (Continued)
135 P05155 Plasma protease C1 inhibitor Extracellular
136 P05121 Plasminogen activator inhibitor 1 Extracellular
137 Q9GZP0 Platelet-derived growth factor D Extracellular
138 P07602 Proactivator polypeptide [Contains: Saposin-A] Extracellular
139 Q15113 Procollagen C-endopeptidase enhancer 1 Extracellular
140 Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Cytoplasm
141 P07737 Profilin-1 Cytoplasm
142 P41222 Prostaglandin-H2 D-isomerase Cytoplasm
143 Q6UXB8 Protease inhibitor 16 Membrane
144 P07237 Protein disulfide-isomerase Cytoplasm
145 Q15084 Protein disulfide-isomerase A6 Cytoplasm
146 P14618 Pyruvate kinase isozymes M1/M2 Cytoplasm
147 Q96D15 Reticulocalbin-3 Cytoplasm
148 Q99969 Retinoic acid receptor responder protein 2 Membrane
149 O75326 Semaphorin-7A Membrane
150 Q12884 Seprase Cytoplasm
151 Q92743 Serine protease HTRA1 Extracellular
152 P02787 Serotransferrin Extracellular
153 P09486 SPARC Extracellular
154 Q9BUD6 Spondin-2 Extracellular
155 Q9BRK5 Stromal cell-derived factor 4 Cytoplasm
156 O00391 Sulfhydryl oxidase 1 Cytoplasm
157 P00441 Superoxide dismutase [Cu-Zn] Cytoplasm
158 Q9Y490 Talin-1 Membrane
159 P24821 Tenascin Extracellular
160 P22105 Tenascin-X Extracellular
161 Q08629 Testican-1 Extracellular
162 P10599 Thioredoxin Cytoplasm
163 Q16881 Thioredoxin reductase 1 Cytoplasm
164 P07996 Thrombospondin-1 Extracellular
165 P35442 Thrombospondin-2 Extracellular
166 Q6FGX5 TIMP1 protein Extracellular
167 Q15582 Transforming growth factor-beta-induced protein ig-h3 Extracellular
168 O14773 Tripeptidyl-peptidase 1 Cytoplasm
169 Q6EMK4 Vasorin Membrane
170 P13611 Versican core protein Extracellular
171 P08670 Vimentin Cytoplasm
172 P04004 Vitronectin Extracellular
173 O76076 WNT1-inducible-signaling pathway protein 2 Extracellular
aThe subcellular location was determined for each protein based on the Ingenuity Pathway Analysis software (Ingenuity Systems).
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convert any N-glycan-modified Asp to an 18O-Asp residue.
The resulting peptides were analyzed by LC-MS/MS using
the previously described method for ITMS and the parent
mass list method for FTMS as described in Materials andMethods. To obtain the parent mass list, the protein se-
quences of the 190 identified secreted proteins from Table 1
and Additional file 1: Table S1 were extracted from the
database. From these sequences, tryptic peptides, with
allowance for two internal missed cleavage sites, that
Figure 3 The functional categories of the primary human adipocyte secretome. The biological function analysis was determined for each
protein based on the Ingenuity Pathway Analysis software (Ingenuity Systems).
Table 2 Human adipocytokines regulated a minimum of 150% under both insulin resistant conditaionsa
No. Protein ID Identified proteins LGPUG/LG HGINS/LG Ave. SC SD Ave. peptides SD
1 Q96D15 Reticulocalbin-3 9.00 8.52 11.50 2.89 3.00 1.15
2 Q9NRN5 Olfactomedin-like protein 3 5.40 7.57 13.60 6.31 3.00 0.00
3 P09603 Macrophage colony-stimulating factor 1 2.98 5.02 5.00 1.87 1.60 0.55
4 Q59H37 Laminin alpha 2 subunit isoform b 1.73 4.60 11.50 6.45 4.50 1.91
5 Q15113 Procollagen C-endopeptidase enhancer 1 1.53 4.11 14.00 3.56 3.75 0.50
6 Q07507 Dermatopontin 2.01 2.93 10.40 2.88 2.00 0.00
7 Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 2.70 2.80 11.17 4.83 3.83 0.98
8 P36222 Chitinase-3-like protein 1 1.49 2.68 26.00 8.05 6.33 0.52
9 P05997 Collagen alpha-2(V) chain 1.55 2.44 9.33 2.89 2.67 0.58
10 Q9Y240 C-type lectin domain family 11 member A 2.07 2.44 11.00 2.00 3.00 0.00
11 Q06828 Fibromodulin 1.76 2.38 15.75 2.06 2.00 1.15
12 O00391 Sulfhydryl oxidase 1 2.20 2.27 8.17 3.06 2.67 0.52
13 P15144 Aminopeptidase N 2.19 2.03 22.00 13.34 4.33 1.86
14 Q99538 Legumain 1.60 1.92 11.67 4.18 1.83 0.98
15 Q6UXB8 Protease inhibitor 16 1.97 1.75 15.75 1.50 2.50 0.58
16 P09486 SPARC 1.48 1.74 263.00 169.53 10.33 1.37
17 P07942 Laminin subunit beta-1 1.48 1.69 63.67 13.34 16.83 1.72
18 O75326 Semaphorin-7A 1.95 1.66 21.17 8.89 3.67 1.03
19 P10909 Clusterin 1.77 1.63 17.00 6.39 3.17 0.75
20 P24821 Tenascin 1.61 1.54 37.33 4.76 9.83 1.72
No. Protein ID Identified proteins LG/LGPUG LG/HGINS Ave. SC SD Ave. peptides SD
1 P61769 Beta-2-microglobulin 2.40 1.90 68.17 35.76 3.17 0.98
2 P00739 Haptoglobin-related protein 1.87 1.66 5.67 0.58 2.00 0.00
3 Q16270 Insulin-like growth factor-binding protein 7 1.75 1.59 19.00 9.76 4.33 1.03
4 O95965 Integrin beta-like protein 1 1.68 1.57 9.00 1.41 3.00 0.00
aLGPUG: low glucose pluse PUGNAc; HGINS: high glucose pluse insulin as two insulin resistant conditions; Ave. SC: average total spectral count and SD:
standard deviation.
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Figure 4 Orthogonal validation of proteomic quantification. Equal amounts of conditioned media from primary human adipocytes was
immunoblotted with antibodies against SPARC or Chitinase-3-like protein 1.
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tained for theoretical mass calculations. Table 3 shows a
total of 91 N-linked glycosylation sites that were identi-
fied on 52 proteins. These sites covered 10.3% of the
theoretical 882 N-linked glycosylation site sequences
generated from the secreted protein list.
Characterization of the human adipocyte glycome
To better define the glycome of human adipocytes, we per-
formed N-linked and O-linked glycan analysis using mass
spectrometry. Glycans were released from whole-cell hu-
man adipocyte extracts by PNGase F for N-linked glycans
and by β-elimination for O-linked glycans as shown in
Figure 2C. Figure 5A shows that the permethylated N-
linked glycans were characterized by full FTMS spectrum
using a LTQ Orbitrap XL (left panel, top) followed by MS/
MS fragmentation by TIM analysis in the ion trap (left
panel, bottom). The fragmentation of a biantennary N-
linked glycan is shown as an example. We used the Glyco-
Workbench to manually interpret a total of 155 N-linked
glycan structures from MS/MS spectra at different charge
states as shown in Additional file 1: Table S3. In Figure 5A
(right panel), we show that 28 of the predominant N-
linked glycans are assigned to a full FTMS and a MS/MS
spectrum.
Figure 5B (left panel) shows a full FTMS spectrum from
an O-linked glycan mixture. 10 of the predominant O-
linked glycans were assigned from the full FTMS spectra
(Figure 5B, bottom panel). A representative fragmentationspectrum is shown for one of the core 2 O-linked glycans
(Figure 5B, right panel). A total of 29 O-linked glycans were
characterized from MS/MS spectra at singly and doubly
charged states as shown in Additional file 1: Table S4.
Relative quantification of the human adipocyte glycome
upon the induction of insulin resistance using 13C labeling
and prevalence
For the comparative quantification of glycans, we per-
formed isotopic labeling using heavy/light iodomethane
(13CH3I and
12CH3I) [78,79]. The
13C/12C ratio from the
sum of the peak areas and the prevalence ratio between
the different treatment conditions were used for relative
quantification. Permethylated glycans were mixed in a 1:1
protein ratio and analyzed in quadruplicate using an LTQ
Orbitrap XL. Figure 6A (left panel) shows the isotopic pairs
of N-linked glycans on a full FTMS spectrum. Figure 6A
(right panel) shows an example of a calculated 13C/12C ratio
from sum of peak area between LG+PUGNAc (LGPUG)
and LG conditions. Additional file 1: Table S5 shows a
total of 48 N-linked glycans that were relatively quanti-
fied between the insulin resistant conditions (LGPUG and
HGINS) and insulin responsive condition (LG) by the aver-
age 13C/12C ratio and the average prevalence ratio. This
approach simultaneously quantified a broad range of N-
glycan structures in a complex mixture; however we did
not observe highly significant changes in N-glycan 13C/12C
ratios or prevalence ratios. Figure 6B (left panel) shows
the isotopic pairs of O-linked glycans on a full FTMS
Table 3 Identification of N-linked glycosylation sites using PNGase F with the incorporation of 18O water in
human adipocytokines
No. Protein ID Identifed proteins N-linked peptidesa
1 P15144 Aminopeptidase N KLN@YTLSQGHR
2 P21810 Biglycan LLQVVYLHSNN@ITK
3 P16870 Carboxypeptidase E GN@ETIVNLIHSTR
4 P07339 Cathepsin D GSLSYLN@VTR
5 P43235 Cathepsin K SN@DTLYIPEWEGR
6 P07711 Cathepsin L YSVAN@DTGFVDIPK
7 P07711 Cathepsin L YSVAN@DTGFVDIPKQEK
8 P10909 Clusterin LAN@LTQGEDQYYLR
9 P02461 Collagen alpha-1(III) chain ASQN@ITYHCK
10 P02461 Collagen alpha-1(III) chain DGSPGGKGDRGEN@GSPGAPGAPGHPGPPGPVGPAGK
11 P20908 Collagen alpha-1(V) chain VYCN@FTAGGSTCVFPDKK
12 P12109 Collagen alpha-1(VI) chain ENYAELLEDAFLKN@VTAQICIDKK
13 P12109 Collagen alpha-1(VI) chain GEDGPAGN@GTEGFPGFPGYPGNR
14 P12109 Collagen alpha-1(VI) chain N@FTAADWGQSR
15 P12109 Collagen alpha-1(VI) chain RN@FTAADWGQSR
16 Q02388 Collagen alpha-1(VII) chain TAPEPVGRVSRLQILN@ASSDVLR
17 Q99715 Collagen alpha-1(XII) chain EAGN@ITTDGYEILGK
18 P08123 Collagen alpha-2(I) chain LLANYASQN@ITYHCK
19 P05997 Collagen alpha-2(V) chain EASQN@ITYICK
20 P12111 Collagen alpha-3(VI) chain GNPGEPGLN@GTTGPKGIR
21 P12111 Collagen alpha-3(VI) chain GPPGVN@GTQGFQGCPGQR
22 P12111 Collagen alpha-3(VI) chain GYPGDEGGPGERGPPGVN@GTQGFQGCPGQR
23 P09871 Complement C1s subcomponent NCGVN@CSGDVFTALIGEIASPNYPKPYPENSR
24 O75462 Cytokine receptor-like factor 1 VLN@ASTLALALANLN@GSR
25 O75462 Cytokine receptor-like factor 1 VVDDVSN@QTSCR
26 P07585 Decorin IADTN@ITSIPQGLPPSLTELHLDGNK
27 P07585 Decorin LGLSFNSISAVDN@GSLANTPHLR
28 Q9UBP4 Dickkopf-related protein 3 GSN@GTICDNQR
29 Q13822 Ectonucleotide pyrophosphatase/phosphodiesterase 2 AEGWEEGPPTVLSDSPWTN@ISGSCK
30 Q13822 Ectonucleotide pyrophosphatase/phosphodiesterase 2 AIIAN@LTCK
31 Q9Y6C2 EMILIN-1 LGALN@SSLQLLEDR
32 P35555 Fibrillin-1 TAIFAFN@ISHVSNK
33 P02751 Fibronectin DQCIVDDITYNVN@DTFHKR
34 P02751 Fibronectin DQCIVDDITYNVN@DTFHK
35 P02751 Fibronectin LDAPTNLQFVN@ETDSTVLVR
36 Q12841 Follistatin-related protein 1 GSN@YSEILDK
37 Q12841 Follistatin-related protein 1 GSN@YSEILDKYFK
38 P09382 Galectin-1 FNAHGDANTIVCNSK
39 Q08380 Galectin-3-binding protein ALGFEN@ATQALGR
40 Q08380 Galectin-3-binding protein DAGVVCTN@ETR
41 Q08380 Galectin-3-binding protein TVIRPFYLTN@SSGVD
42 P00738 Haptoglobin VVLHPN@YSQVDIGLIK
43 O75629 Human Protein CREG1 LN@ITNIWVLDYFGGPK
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Table 3 Identification of N-linked glycosylation sites using PNGase F with the incorporation of 18O water in
human adipocytokines (Continued)
44 P17936 Insulin-like growth factor-binding protein 3 GLCVN@ASAVSR
45 O14498 ISLR SLDLSHNLISDFAWSDLHN@LSALQLLK
46 Q8NHP8 LAMA-like protein 2 SDLNPAN@GSYPFKALR
47 Q16363 Laminin subunit alpha-4 DAVRN@LTEVVPQLLDQLR
48 Q16363 Laminin subunit alpha-4 FYFGGSPISAQYAN@FTGCISNAYFTR
49 Q16363 Laminin subunit alpha-4 LITEEAN@R
50 Q16363 Laminin subunit alpha-4 LTLSELDDIIKN@ASGIYAEIDGAK
51 Q16363 Laminin subunit alpha-4 RPASN@VSASIQR
52 P07942 Laminin subunit beta-1 LSDTTSQSN@STAK
53 P11047 Laminin subunit gamma-1 VN@NTLSSQISR
54 P11047 Laminin subunit gamma-1 KYEQAKN@ISQDLEK
55 P11047 Laminin subunit gamma-1 LLNN@LTSIK
56 P11047 Laminin subunit gamma-1 TAN@DTSTEAYNLLLR
57 P11047 Laminin subunit gamma-1 TLAGEN@QTAFEIEELNR
58 P11047 Laminin subunit gamma-1 VNDN@KTAAEEALR
59 Q14767 Latent-transforming growth factor beta-binding protein 2 DGTQQAVPLEHPSSPWGLN@LTEK
60 P51884 Lumican AFEN@VTDLQWLILDHNLLENSK
61 P51884 Lumican LGSFEGLVN@LTFIHLQHNR
62 P51884 Lumican LHINHNN@LTESVGPLPK
63 P13473 Lysosome-associated membrane glycoprotein 2 IAVQFGPGFSWIAN@FTK
64 P01033 Metalloproteinase inhibitor 1 AKFVGTPEVN@QTTLYQR
65 P01033 Metalloproteinase inhibitor 1 FVGTPEVN@QTTLYQR
66 P01033 Metalloproteinase inhibitor 1 SHN@RSEEFLIAGK
67 Q9NRN5 Olfactomedin-like protein 3 IYVLDGTQN@DTAFVFPR
68 P26022 Pentraxin-related protein PTX3 ATDVLN@K
69 Q15063 Periostin EVN@DTLLVNELK
70 Q15063 Periostin IFLKEVN@DTLLVNELK
71 P98160 Perlecan SLTQGSLIVGDLAPVN@GTSQGK
72 P55058 Phospholipid transfer protein VSN@VSCQASVSR
73 P36955 Pigment epithelium-derived factor VTQN@LTLIEESLTSEFIHDIDR
74 P36955 Pigment epithelium-derived factor VTQN@LTLIEESLTSEFIHDIDRELK
75 P05155 Plasma protease C1 inhibitor VGQLQLSHN@LSLVILVPQNLK
76 P05155 Plasma protease C1 inhibitor VLSN@NSDANLELINTWVAK
77 P07602 Proactivator polypeptide [Contains: Saposin-A] TN@STFVQALVEHVK
78 P07602 Proactivator polypeptide [Contains: Saposin-A] LIDNN@KTEK
79 P07602 Proactivator polypeptide [Contains: Saposin-A] LIDNN@KTEKEILDAFDK
80 P07602 Proactivator polypeptide [Contains: Saposin-A] NLEKN@STK
81 P07602 Proactivator polypeptide [Contains: Saposin-A] NLEKN@STKQEILAALEK
82 P07602 Proactivator polypeptide [Contains: Saposin-A] TN@STFVQALVEHVKEECDR
83 P09486 SPARC VCSNDN@K
84 P09486 SPARC VCSNDN@KTFDSSCHFFATK
85 P24821 Tenascin N@TTSYVLR
86 P24821 Tenascin LN@YSLPTGQWVGVQLPR
87 P07996 Thrombospondin-1 VVN@STTGPGEHLR
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Table 3 Identification of N-linked glycosylation sites using PNGase F with the incorporation of 18O water in
human adipocytokines (Continued)
88 P35442 Thrombospondin-2 VVN@STTGTGEHLR
89 Q6FGX5 TIMP1 protein FVGTPEVN@QTTLYQR
90 Q6FGX5 TIMP1 protein SHN@RSEEFLIAGK
91 Q6EMK4 Vasorin LHEITN@ETFR
aAn @ indicates the site of N-linked glycosylation.
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calculated 13C/12C ratio from the sum of peak areas be-
tween LGPUG and LG conditions. Additional file 1: Table
S6 shows a total of 12 O-linked glycans that were rela-
tively quantified between insulin resistant and insulin sen-
sitive conditions. We did not observe highly significant
changes in O-glycan 13C/12C ratios or prevalence ratios.
Discussion
Several groups have reported the rodent adipocyte secre-
tome during insulin resistance, but there have been fewer
such studies performed with human adipocytes [25,80-82].
It is advantageous to investigate the secretome of human
adipose tissue because there are bound to be differences
between the rodent and human secretome [8]. The differ-
ences in the secretome of human adipose tissue have been
investigated during adipogenesis and between different
fat pad depots [83-86]. Other studies have characterized
the secretome without quantification [87,88]. Another
approach has been to study a limited list of known adi-
pocytokines during insulin sensitivity and insulin resist-
ance [89,90]. Therefore, our study fills an important gap
in the literature by taking a discovery approach to char-
acterizing and quantifying the human adipocyte secre-
tome in both insulin sensitive and two different insulin
resistance conditions. In addition, we characterize and
quantify the glycome of human adipocytes, which has
not been described to our knowledge.
We report a total of 193 secreted proteins from hu-
man adipocytes (Table 1 and Additional file 1: Table S1).
Using Ingenuity Pathways Analysis we determined that
many of the secreted proteins were enzymes, peptidases,
or other functions (Figure 3). The largest pool of identified
proteins from the other category corresponds to extracellu-
lar matrix proteins. A common theme among the adipose
tissue secretome studies is that extracellular matrix (ECM)
proteins, ECM remodelers, inflammatory, and angiogenesis
proteins are highly represented [7,81,87,91]. The accumula-
tion of fat mass during obesity requires extensive tissue re-
modeling that is accomplished by ECM remodelers. The
remodeling can generate an inflammatory response during
obesity and insulin resistance due to limited angiogenesis,
localized hypoxia, adipocyte necrosis, increased fibrosis,
altered adipocytokine secretion, and M1-stage macro-
phage and other immune cell infiltration [4,92-96]. Manyof the adipocytokines we identified, such as SPARC and
Chitinase-3-like protein 1, have been implicated in inflam-
mation [97,98]. In addition, tissue remodeling requires
extensive crosstalk between the different cell types that
comprise adipose tissue. Several of the adipocytokines we
identified, such as Gelsolin, Calreticulin, and Cathepsin D,
may be expressed in cell types other than adipocytes
[87,99]. By using primary adipocytes instead of a cell line,
the secretome we identified better represents the physio-
logical status of adipose tissue. In the future, these identi-
fied adipocytokines may potentially be used as prognostic/
diagnostic biomarkers for metabolic syndrome, T2DM,
and other complications.
We generated insulin resistance in the human adipo-
cytes by both directly and indirectly modulating O-
GlcNAc levels. The elevation of O-GlcNAc levels has
been shown to be sufficient to induce insulin resistance in
many systems [19-24]. We have previously demonstrated
that the induction of insulin resistance in this way in ro-
dent adipocytes alters the secretion of several adipocyto-
kines [25]. Here, we showed that 20 and 4 adipocytokines
were upregulated or downregulated, respectively, upon the
transition to insulin resistance by both directly and indir-
ectly modulating O-GlcNAc levels (Table 2). We also iden-
tified 28 and 8 adipocytokines that were upregulated or
downregulated, respectively, upon the induction of insulin
resistance by one of the two methods (Additional file 1:
Table S2). In this study, we find that Sulfhydryl oxidase
1 (Quiescin Q6), laminin B1, and Chitinase-3-like pro-
tein 1 are upregulated during both insulin resistant con-
ditions, which was also observed in the rodent study.
SPARC was upregulated in both insulin resistant condi-
tions in human adipocytes and was found to be upregu-
lated in HG+ INS in rodent adipocytes by proteomics.
Four other proteins were observed to be regulated by insu-
lin resistance in both rodent and human adipocytes; how-
ever, the regulation was slightly different between species.
Thioredoxin was downregulated in both insulin resistant
conditions in rodent adipocytes and during HG+ INS in
human adipocytes but was upregulated during LG + PUG
in human adipocytes. Gelsolin was upregulated in both in-
sulin resistant conditions in rodent adipocytes and during
HG+ INS in human adipocytes but was not regulated by
LG + PUG. Fibulin 2 was downregulated in both insulin
resistant conditions in rodent adipocytes but was not
Figure 5 (See legend on next page.)
Lim et al. Clinical Proteomics 2014, 11:20 Page 17 of 23
http://www.clinicalproteomicsjournal.com/content/11/1/20
(See figure on previous page.)
Figure 5 Characterization of the primary human adipocyte glycome by MS/MS and TIM scan. (A) Upper left panel: a full FTMS spectrum of
the N-linked glycan mixture, lower left panel: the characterization of a biantennary complex N-linked glycan structure by MS/MS fragmentation,
right panel: a list of predominant N-linked glycans. (B) Upper left panel: a full FTMS spectrum of the O-linked glycan mixture, upper right panel:
the characterization of a core 2 O-linked glycan structure by MS/MS fragmentation, lower panel: a list of predominant O-linked glycans. (pink star): Xyl,
(red inverted triangle): Fuc, (blue circle): Glc, (green circle): Man, (yellow circle): Gal, (blue square): GlcNAc, (yellow square): GalNAc, and (violet
diamond): NeuAc.
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respectively, in human adipocytes. From these exam-
ples, it is clear that there are differences in adipocyto-
kine secretion between rodents and humans. Because
the proteome sample is extremely complex, we may not
have achieved sufficient resolution to quantify some of
the proteins that were observed in both rodent and hu-
man adipocyte secretomes, such as Angiotensinogen, Ca-
thepsin B, and Spondin 1 [25,100]. Because we assigned
significance to a relatively small fold change (1.5 fold) for
quantification, we verified the regulation of two adipocyto-
kines that changed by 1.5 fold by an independent, orthog-
onal method. Both SPARC and Chitinase-3-like protein 1
protein levels were altered in a similar manner as mea-
sured by both quantitative proteomics and immunoblot-
ting (Figure 4). In addition, the regulation of these proteins
by O-GlcNAc was verified using a more OGA-specific N-
acetyglucosaminidase inhibitor, GlcNAcstatin.
The inclusion of an insulin resistance condition generated
by directly modulating O-GlcNAc levels in our proteomic
study helped us to better define the proteins regulated by
O-GlcNAc in human adipocytes. The O-GlcNAc modifica-
tion is found on hundreds in nucleocytosolic proteins and
can affect protein function in diverse ways, such as protein-
protein interactions, protein degradation, interplay with
phosphorylation, localization, and transcriptional activation
[101]. Compiling a list of proteins modulated by O-GlcNAc
is the first step in understanding the mechanism of how
O-GlcNAc affects adipocytokine expression. We have
used the data generated by our previous rodent prote-
omic study to investigate the transcriptional regulation
of adipocytokines by global O-GlcNAc levels (unpub-
lished data). Although several studies have associated
elevated O-GlcNAc levels with adipocytokine expres-
sion, no specific molecular mechanism has been reported
[13-16,21,102,103].
We also characterize the N-linked and O-linked glycome
for human adipocytes. Glycosylation and other PTM’s pro-
vide an additional layer of regulatory complexity to ex-
pressed proteins. To understand the full functionality of
a protein, one must know the state of the PTM’s. Since
secretory proteins, such as adipocytokines, are exposed to
the glycosylation machinery that reside in the ER and Golgi
apparatus as they make their way through the secretory
pathway, they often have a high degree of complex glyco-
sylation. The subset of glycans expressed by cells dependson multiple factors, such as developmental stage, tissue
type, and the genetic and physiological state of the cell. It
is not known whether adipocytes change glycan expression
patterns in response to insulin resistance. Since glyco-
sylation can affect diverse processes that are relevant to
adipose tissue remodeling in obesity, such as cell-cell in-
teractions, growth factor sequestration, cytokine activation,
and cell migration, there is a need to define the adipocyte
glycome [34,104,105].
Characterizing the glycome poses many challenges be-
cause there is no template for modification, as in DNA,
and there is an incredible diversity of glycoforms. Mass
spectrometry can provide both structural and abundance
information using a small amount of material from a
relatively complex mixture [106]. However, it is still difficult
to assign specific glycoforms to specific protein residues in
a complex mixture. To determine sites of N-glycosylation
on the secreted proteins, we used PNGase F and 18O water
to convert the glycan-modified Asn to an 18O-Asp residue,
thereby leaving a chemical marker of the glycosylation
site. We identified 91 sites on 51 proteins of N-linked
glycosylation by Orbitrap mass spectrometer using the
parent mass list obtained from theoretical consensus se-
quence in the secretome list (Table 3). For relative glycan
quantification, we permethylated using heavy or light iodo-
methane (13CH3I and
12CH3I) and used prevalence data.
The use of isotopic labels allows for mixing of the samples
to be compared before analysis, thus providing an internal
standard and preventing run to run technical variation
[49,78]. These techniques allow us to determine the full
diversity and changes in major and minor adipocyte gly-
cans during insulin sensitive and resistant conditions. We
characterized a total of 155 N-linked glycans and 29 of
O-linked glycans (Figure 5, Additional file 1: Table S3,
Table S4). The results presented here demonstrate that
the human adipocytes are expressing extended hybrid
and complex N-linked glycans, in addition to high man-
nose glycans. Adipose tissues possess the biosynthetic
ability to generate diverse O-linked glycans such as core
structure, O-glucose glycans, and O-fucose glycans.
Following characterization, we determined the change
in glycan prevalence during insulin resistance using iso-
topic and prevalence ratios. We quantified 48 N-linked
glycans and 12 O-linked glycans (Figure 6, Additional
file 1: Tables S5-S6). Our results showed that changes of
glycan prevalence were not statistically different between
Figure 6 (See legend on next page.)
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Figure 6 Relative quantification of the primary human adipocytes glycome during insulin resistance using 13C/12C labeling. (A) Upper
left panel: a full FTMS spectrum of 13C/12C labeled N-linked glycans in HGINS and LG, upper right panel: a FTMS spectrum to calculate 13C/12C
ratios from the sum of isotopic peak areas between the isotopic pairs, lower panel: a list of relative ratios for HGINS and LG for predominant
N-linked glycans. (B) Upper left panel: a full FTMS spectrum of 13C/12C labeled O-linked glycans in LGPUG and LG, upper right panel: a FTMS
spectrum to calculate 13C/12C ratios from the sum of isotopic peak areas between the isotopic pairs, lower panel: a list of relative ratios for LGPUG
and LG for predominant O-linked glycans.
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been suggested that altering the intracellular UDP-GlcNAc
pool, such as during increased glucose flux, changes the
degree of N-glycan branching in an ultrasensitive manner
[37]. While it is clear that the induction of insulin resist-
ance in adipocytes massively upregulates intracellular
glycosylation (Figure 1), we did not observe significant
changes in complex glycosylation. This suggests that
changes in complex glycosylation are not necessary for
the induction of insulin resistance; although we cannot
rule out that they play a role in insulin resistance that
occurs over a long period of time. Since insulin resist-
ance was generated by treatment for 40 hours, it is pos-
sible that the changes in glycan structure had not had
time to significantly change.
In conclusion, we have characterized the secretome and
glycome of primary human adipocytes during insulin re-
sistance using a proteomic approach. We generated insulin
resistance by either directly or indirectly modulating O-
GlcNAc levels, which provides a list of adipocytokines that
are modulated by O-GlcNAc levels. Adipocytokine and
glycan levels were quantified between insulin sensitive and
insulin resistant conditions and sites of N-glycosylation
were identified. This study helps to define the secretome
of primary human adipocytes during insulin resistance
and helps to characterize and quantify the previously
unknown primary adipocyte glycome. Finally, while ele-
vated glucose levels and flux through the hexosamine
pathway could theoretically alter both complex glycosyla-
tion and O-GlcNAc levels, our findings clearly demonstrate,
under the short time frame used here where significant
changes were observed in adipocytokine secretion but not
in complex glycosylation, that only elevation in O-GlcNAc
levels correlate with the observed changes in adipocytokine
secretion.Additional file
Additional file 1: Table S1. The list of secreted proteins identified by
single peptide detection from primary human adipocytes. Table S2.
Human adipocytokines regulated a minimum of 150% under one of the
insulin resistant conditions. Table S3. Characterization of total N-linked
glycans from primary human adipocytes by MS/MS and TIM scan.
Table S4. Characterization of total O-linked glycans from primary human
adipocytes by MS/MS and TIM scan. Table S5. Relative quantification of
N-linked glycans from primary human adipocytes between insulin resistant
conditions and insulin responsive condition by 13C/12C ratio and prevalenceratio. Table S6. Relative quantification of O-linked glycans from human
adipocytes between insulin resistant conditions and insulin responsive
condition by 13C/12C ratio and prevalence ratio.
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